Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
June 08, 2024 08:15 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
June 07, 2024 15:24 ET
|
The Rosen Law Firm PA
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September...
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
June 06, 2024 14:28 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Akero Therapeutics, Inc....
DEADLINE ALERT for CMP, EXAI, AKRO, and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
June 06, 2024 12:07 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, June 06, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. – AKRO
June 05, 2024 22:56 ET
|
SkyMedia, LLC
NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a...
AKRO STOCKHOLDERS - Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
June 05, 2024 16:18 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Akero Therapeutics, Inc. (AKRO) Misled Investors Regarding the Viability of its Trial Drug Candidate
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO
June 05, 2024 13:13 ET
|
Pomerantz LLP
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO). Such...
DEADLINE ALERT for ADSK, CMP, AKRO, EXAI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
June 05, 2024 12:00 ET
|
Law Offices of Howard G. Smith
BENSALEM, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
June 05, 2024 11:15 ET
|
Faruqi & Faruqi LLP
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. (“Akero” or the...
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
June 05, 2024 10:20 ET
|
Schall Law
The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm